The CD40 agonist HERA-CD40L results in enhanced activation of antigen presenting cells, promoting an anti-tumor effect alone and in combination with radiotherapy

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'The CD40 agonist HERA-CD40L results in enhanced activation of antigen presenting cells, promoting an anti-tumor effect alone and in combination with radiotherapy'. Together they form a unique fingerprint.

Immunology and Microbiology